KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Non-Current Assets (2018 - 2025)

Twist Bioscience (TWST) has disclosed Non-Current Assets for 6 consecutive years, with $364.7 million as the latest value for Q1 2023.

  • On a quarterly basis, Non-Current Assets rose 2.07% to $364.7 million in Q1 2023 year-over-year; TTM through Mar 2023 was $462.7 million, a 56.46% decrease, with the full-year FY2022 number at $364.9 million, up 134.51% from a year prior.
  • Non-Current Assets was $364.7 million for Q1 2023 at Twist Bioscience, roughly flat from $364.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $401.2 million in Q4 2021 to a low of -$634.4 million in Q4 2020.
  • A 5-year average of $32.2 million and a median of $63.8 million in 2020 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: plummeted 1524.88% in 2020, then soared 415.6% in 2022.
  • Twist Bioscience's Non-Current Assets stood at $63.0 million in 2019, then plummeted by 1107.2% to -$634.4 million in 2020, then skyrocketed by 163.23% to $401.2 million in 2021, then fell by 9.04% to $364.9 million in 2022, then dropped by 0.07% to $364.7 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Non-Current Assets are $364.7 million (Q1 2023), $364.9 million (Q3 2022), and -$624.1 million (Q2 2022).